Related Experiment Video
Updated: Dec 13, 2025

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
The Antisense long noncoding RNA AGAP2-AS1 regulates cell proliferation and metastasis in Epithelial Ovarian Cancer
Zheng Tingting1,2,3,4, Lin Xiaojing1,2,3, Tang Xiaoyan1,2,3
1Department of Gynaecology, Obstetrics and Gynaecology Hospital, Fudan University, 419 Fangxie Road, Shanghai 200011, China Shanghai 200011, China.
Abstract:
Antisense long noncoding RNAs serve as important regulators of protein-coding genes and contribute to tumorigenesis and metastasis. AGAP2-AS1, an antisense lncRNA transcribed from AGAP2, is involved in various cancer types. However, the clinical significance, biological roles and regulatory mechanisms of AGAP2-AS1 in epithelial ovarian cancer (EOC) have not been thoroughly elucidated to date. In this study, we demonstrated the expression pattern and biological roles of AGAP2-AS1 in EOC. Clinically, AGAP2-AS1 expression was decreased in EOC tissues compared to that in the controls. Low expression of AGAP2-AS1 was associated with advanced FIGO stage, high histological grade, serous subtype and lymph node metastasis in patients with EOC. AGAP2-AS1 inhibited cell migration, invasion and proliferation in vitro. AGAP2-AS1 suppressed tumor growth in vivo. Mechanistically, AGAP2-AS1 inhibited cell metastasis and proliferation by downregulating KRAS, FGFR4, and CTSK and suppressing epithelial-mesenchymal transition. In conclusion, we provide the first evidence for the tumor-suppressing effect of AGAP2-AS1 in EOC and demonstrate that AGAP2-AS1 may represent a promising therapeutic target for EOC patients.
Insights
Antisense long noncoding RNA AGAP2-AS1 acts as a tumor suppressor in epithelial ovarian cancer (EOC). Its decreased expression correlates with advanced EOC, and it inhibits cancer progression by downregulating key genes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Antisense long noncoding RNAs (lncRNAs) regulate gene expression and are implicated in cancer.
- AGAP2-AS1, an antisense lncRNA, is involved in various cancers, but its role in epithelial ovarian cancer (EOC) is unclear.
Purpose of the Study:
- To investigate the clinical significance, biological functions, and regulatory mechanisms of AGAP2-AS1 in EOC.
- To evaluate AGAP2-AS1 as a potential therapeutic target for EOC.
Main Methods:
- Analysis of AGAP2-AS1 expression in EOC tissues and correlation with clinical parameters.
- In vitro assays to assess the effects of AGAP2-AS1 on cell migration, invasion, and proliferation.
- In vivo studies to evaluate tumor growth suppression by AGAP2-AS1.
- Mechanistic studies to identify genes and pathways regulated by AGAP2-AS1.
Main Results:
- AGAP2-AS1 expression was significantly decreased in EOC tissues compared to controls.
- Low AGAP2-AS1 expression was associated with advanced FIGO stage, high histological grade, serous subtype, and lymph node metastasis.
- AGAP2-AS1 inhibited EOC cell migration, invasion, and proliferation in vitro and suppressed tumor growth in vivo.
- AGAP2-AS1 exerted its tumor-suppressive effects by downregulating KRAS, FGFR4, and CTSK, and suppressing epithelial-mesenchymal transition.
Conclusions:
- AGAP2-AS1 functions as a tumor suppressor in EOC.
- AGAP2-AS1 may serve as a valuable prognostic biomarker and a potential therapeutic target for EOC.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Experimental RNAi
MicroRNAs
MicroRNAs
piRNA - Piwi-interacting RNAs
